BioXcel Therapeutics logo
BioXcel Therapeutics BTAI
$ 0.59 0.0%

Quarterly report 2024-Q3
added 11-14-2024

report update icon

BioXcel Therapeutics Financial Statements 2011-2024 | BTAI

Annual Financial Statements BioXcel Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

81.9 M 78.7 M 475 M 1 B 284 M 79.9 M - - - - - - -

Shares

29.1 M 28 M 26.4 M 21.7 M 16.3 M 14.6 M - - - - - - -

Historical Prices

2.81 2.81 18.3 53.6 37.5 8.48 - - - - - - -

Net Income

-179 M -166 M -107 M -82.2 M -33 M -19.3 M -4.54 M -2.12 M - - - - -

Revenue

1.38 M 375 K - 24.3 - - - - - - - - -

Cost of Revenue

1.26 M 20 K - - - - - - - - - - -

Gross Profit

- - - 24.3 - - - - - - - - -

Operating Income

-172 M -160 M -107 M -82.3 M -33.6 M -20 M -4.54 M - - - - - -

Interest Expense

13.3 M 8.21 M 40 K 27 K 20 K - - - - - - - -

EBITDA

-171 M -159 M -107 M -82.1 M -33.4 M -19.9 M -4.54 M -2.12 M - - - - -

Operating Expenses

- - 107 M 82.3 M 33.6 M 20 M - - - - - - -

General and Administrative Expenses

83.4 M 68.8 M 54.2 M 24.3 M 7.8 M 5.4 M 1.85 M 721 K - - - - -

All numbers in USD currency

Quarterly Income Statement BioXcel Therapeutics

2024-Q3 2024-Q2 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

42.4 M 40.3 M 29.9 M 29.3 M 29.2 M - 28.1 M 28 M 28 M 28 M 28 M 28 M 25 M 24.5 M 24.4 M 23 M 20.3 M 19 M 18.1 M 15.8 M 15.7 M 15.7 M 15.7 M 15.6 M 15.6 M 11.5 M 9.91 M 9.48 M 9.48 M 9.48 M - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-13.6 M -8.3 M - -50.5 M -53.5 M -52.8 M - -41.8 M -37.7 M -31.5 M - -26.8 M -27.6 M -26.4 M - -24.8 M -21.4 M -14.9 M - -9.02 M -8.47 M -7.2 M - -4.89 M -3.03 M -4.28 M - -917 K -565 K -529 K - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

214 K 1.1 M - 341 K 457 K - - 137 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

1.17 M 62 K - 512 K 26 K - - 11 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-15.3 M -17.3 M - -48.3 M -52.4 M - - -39 M -36.3 M -31.5 M - -26.8 M -27.6 M -26.4 M - -24.8 M -21.4 M -15 M - -9.13 M -8.64 M -7.42 M - -5.12 M -3.24 M -4.29 M - -917 K -565 K -529 K - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

4.82 M 12 M - -5 K 537 K - - 3.7 M 1.59 M 7 K - 11 K 16 K 7 K - 5 K 12 K 6 K - 18 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-15.2 M -17.2 M - -48.2 M -52.3 M - - -38.9 M -36.2 M -31.4 M - -26.7 M -27.5 M -26.3 M - -24.7 M -21.4 M -14.9 M - -8.92 M -8.51 M -7.38 M - -5.11 M -3.24 M -4.29 M - -916 K -565 K -528 K - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - - - - 36.3 M 31.5 M - 26.8 M 27.6 M 26.4 M - 24.8 M 21.4 M 15 M - 9.13 M 8.64 M 7.42 M - 5.12 M 3.24 M 4.29 M - 917 K 565 K - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

7.68 M 9.45 M - 24.3 M 25.9 M - - 17.1 M 18.4 M 12.9 M - 14.9 M 14.1 M 11.6 M - 8.45 M 3.53 M 2.62 M - 2.01 M 2.13 M 1.74 M - 1.3 M 1.46 M 1.35 M - 298 K 241 K 208 K - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency